US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Spirit Realty Capital

42.31

+0.0000

Volume:- -

Turnover:- -

Market Cap:5.99B

PE:24.03

High:42.31

Open:42.31

Low:42.31

Close:42.31

Loading ...

Overview Company News Filings

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring

Singapore Red Cross to send another S$600,000 in aid to Myanmar in wake of deadly quake

Bitget Onchain Trading Launched OPAIUM, Fartcoin2, CREW, and Other Tokens

SECuRE trial update: First patient treated in the Phase II Cohort Expansion

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Singapore Red Cross sends additional humanitarian aid worth S$550,000 to Myanmar earthquake survivors

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

Singapore Red Cross pledges S$150,000 to support Myanmar, Thailand quake relief

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.

Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today

Guess which ASX 200 biotech stock is jumping 7% on big news

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Island completes dosing in phase 2b arm of mosquito-borne dengue trial

SigmaRoc: Strong Market Position, Decarbonization Success, and Undervalued Investment Potential

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Realty Income Announces 2024 Dividend Tax Allocation for Realty Income Corporation and Spirit Realty Capital, Inc.

Island completes phase 2b enrolments in dengue fever trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SRC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SRC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SRC\",,,,,undefined,":{"symbol":"SRC","market":"US","secType":"STK","nameCN":"Spirit Realty Capital","latestPrice":42.31,"timestamp":1746640318680,"preClose":42.31,"halted":0,"volume":0,"delay":0,"floatShares":140027263,"shares":141552606,"eps":1.76103,"marketStatus":"Trading","change":0,"latestTime":"05-07 13:51:58 EDT","open":42.31,"high":42.31,"low":42.31,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.76103,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746648000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1348113600000,"exchange":"NYSE","adjPreClose":42.31,"dividendRate":0.062836,"volumeRatio":0,"impliedVol":0.3737,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SRC\",,,,,undefined,":{"symbol":"SRC","floatShares":140027263,"roa":"2.42%","roe":"5.74%","lyrEps":2.040987,"shares":141552606,"dividePrice":2.6586,"high":42.31,"amplitude":0,"preClose":42.31,"low":42.31,"week52Low":42.31,"pbRate":"1.38","psRate":"7.94","week52High":42.31,"institutionHeld":0,"latestPrice":42.31,"eps":1.76103,"divideRate":0.062836,"volume":0,"delay":0,"ttmEps":1.76103,"open":42.31,"prevYearClose":42.31,"prevWeekClose":42.31,"prevMonthClose":42.31,"prevQuarterClose":42.31,"fiveDayClose":42.31,"twentyDayClose":42.31,"sixtyDayClose":42.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SRC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530409743","title":"iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring","url":"https://stock-news.laohu8.com/highlight/detail?id=2530409743","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530409743?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:05","pubTimestamp":1745841900,"startTime":"0","endTime":"0","summary":"Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups.Latest data showed Zio LTCM was associated with higher diagnostic yield and lower likelihood of repeat testing and cardiovascular events compared to all other LTCM products.SAN FRANCISCO, April 28, 2025  -- iRhythm Technologies, Inc.  announced results from a large real-world retrospective analysis presented at the Heart Rhythm Society’s annual meeting, HRS2025, held April 24–27 in San Diego, CA, The Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries  study—drawing on claims data from a cohort of 428,707 commercially insured patients—represents the largest real-world comparative evaluation of ambulatory cardiac monitoring  among this population to date, and reinforces the clinical superiority of the Zio long-term continuous monitoring  service.“O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/irhythm-presents-real-world-data-120500535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0498741114.HKD","LU1169589451.USD","BK4017","LU1223083913.SGD","AEM","SG9999001143.SGD","BK4082","LU1169590202.USD","LU2308191902.HKD","LU1223082196.USD","BK4129","IRTC","LU0496367417.USD","BK4563","LU0498741890.SGD","BK4585","BK4080","SRC","MI","ACM","BK4516","BK4077","BK4231"],"gpt_icon":0},{"id":"2529939648","title":"Singapore Red Cross to send another S$600,000 in aid to Myanmar in wake of deadly quake","url":"https://stock-news.laohu8.com/highlight/detail?id=2529939648","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529939648?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:31","pubTimestamp":1745494260,"startTime":"0","endTime":"0","summary":"The organisation's latest tranche of support will also include 810 tents to Gaza and S$600,000 to Syria. \n ","market":"sg","thumbnail":"https://dam.mediacorp.sg/image/upload/s--OJH6i_3Y--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/04/24/p-mmr2216_mod.jpg?itok=2zHCV3km","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--OJH6i_3Y--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/04/24/p-mmr2216_mod.jpg?itok=2zHCV3km"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/singapore-red-cross-myanmar-gaza-syria-humanitarian-aid-5086291","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4231","SRC","BK4080"],"gpt_icon":0},{"id":"2529223506","title":"Bitget Onchain Trading Launched OPAIUM, Fartcoin2, CREW, and Other Tokens","url":"https://stock-news.laohu8.com/highlight/detail?id=2529223506","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529223506?lang=en_us&edition=fundamental","pubTime":"2025-04-24 16:03","pubTimestamp":1745481780,"startTime":"0","endTime":"0","summary":"BlockBeats News, on April 24, Bitget's Onchain Trading launched the MEME tokens OPAIUM, Fartcoin2, CREW, CHAD, SRC, JOS from the Solana ecosystem. Users can start trading on the on-chain trading section.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/291043","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["SOL.USD.HKCC","BK4231","SRC","MEME","BK4080","CHAD"],"gpt_icon":0},{"id":"2527412783","title":"SECuRE trial update: First patient treated in the Phase II Cohort Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412783","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412783?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:02","pubTimestamp":1744722120,"startTime":"0","endTime":"0","summary":"The first of the planned 24 participants in the Cohort Expansion Phase  of theSECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee  after the successful completion of the Dose Escalation Phase to commence enrollment for the Cohort Expansion Phase at the 8 GBq dose level, with an increase of the number of cycles from up to 4 to up to 6.This participant will be treated with the combination of 8GBq of 67Cu-SAR-bisPSMA with enzalutamide , as per the recent protocol amendment to include a subset of participants in the Cohort Expansion Phase to receive this combination.The recently amended SECuRE trial protocol will also focus on the evaluation of metastatic castration-resistant prostate cancer  participants in the pre-chemotherapy setting. This aligns with Clarity's strategy of bringing 67Cu-SAR-bisPSMA to earlier stages of the disease and is based on its promising safety and efficacy data, esp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/secure-trial-first-patient-treated-130200983.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/secure-trial-first-patient-treated-130200983.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4533","BK4084","BK4135","BK7001","SAR","CU6.AU","SAR.AU","TGA","BK4585","PSA","BK7096","TGA.AU","BK4213","BK4231","SRC","BK4217","BK4080","BK4588"],"gpt_icon":0},{"id":"2526255278","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526255278","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526255278?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:02","pubTimestamp":1744282920,"startTime":"0","endTime":"0","summary":"–SRC recommended that the trial escalate to the next dose level of 30mg capsule –。“We are seeing substantial enrollment demand and have already identified Cohort 6 patients. In addition, we continue to observe substantial exposure levels of PAS-004, and remain excited about the possibility of delivering relevant pERK inhibition below the no observed adverse effect levels  as we modeled and observed during our previously conducted nine-month chronic toxicity studies. The on label rash rate for both approved MEKi for NF1 exceeds 80% which leads to patients discontinuing who otherwise should remain on treatment for longer periods of time”, stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “We will provide additional safety, pharmacokinetic  and pharmacodynamic  data over the next several weeks.”This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Ac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-positive-safety-110200309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","AEIS","BK4157","LU1169589451.USD","BK4218","BK4135","BK4181","KTTA","BK4023","BK4007","BK4080","LU1169590202.USD","CNS","IE00B66KJ199.SGD","IE00B19Z4B17.USD","KTTAW","BK4231","PD","LENZ","BK4139","SRC","IE00B7SZL793.SGD","PK"],"gpt_icon":0},{"id":"2526586063","title":"Singapore Red Cross sends additional humanitarian aid worth S$550,000 to Myanmar earthquake survivors","url":"https://stock-news.laohu8.com/highlight/detail?id=2526586063","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526586063?lang=en_us&edition=fundamental","pubTime":"2025-04-10 15:03","pubTimestamp":1744268597,"startTime":"0","endTime":"0","summary":"SINGAPORE: The Singapore Red Cross  has sent an additional tranche of humanitarian aid to provide urgent relief to the communities affected by last month’s earthquake in Myanmar, the organisation said in a news release on Thursday .The latest tranche includes supplies like hygiene kits for families, women’s hygiene kits, jerrycans for the collection and storage of clean water, plastic mats, mosquito nets and tarpaulins.The supplies are expected to support about 8,000 households across the regions affected by the quake, SRC said.“Together, these contributions are worth an estimated S$550,000 , and are expected to benefit around 80,000 persons,” SRC said.To support the Singapore Emergency Medical Team  deployed last week, SRC worked with their Myanmar counterparts to deploy local volunteers and two ambulances to transfer patients between the SGEMT field hospital near Myanmar's capital Naypyidaw and Mandalay General Hospital.Besides humanitarian aid, SRC also supported affected communitie","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--apa7sS7l--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/04/10/water_filters_and_solar_lamps_by_src_0.jpeg?itok=is-qinZL","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--apa7sS7l--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/04/10/water_filters_and_solar_lamps_by_src_0.jpeg?itok=is-qinZL"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/myanmar-earthquake-singapore-red-cross-sends-additional-humanitarian-aid-worth-s550000-survivors-5056646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["MRC","SRC","BK4080","BK4231","BK4104"],"gpt_icon":0},{"id":"2524017002","title":"Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2524017002","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524017002?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:00","pubTimestamp":1743771600,"startTime":"0","endTime":"0","summary":"Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3055960/0/en/Sonnet-s-SON-1010-Demonstrates-a-Strong-Safety-Profile-in-Combination-with-Atezolizumab-for-Treatment-of-Platinum-Resistant-Ovarian-Cancer-Including-a-Partial-Response-at-the-Highe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4108","BK4567","MTD","BK4531","SG9999011746.SGD","BK4213","01698","BK4139","PK","BK4218","BK4585","PROC","LU2039709279.SGD","BK4588","LU1721428933.USD","LU1093756325.SGD","LU1093756168.USD","SONN","BK4571","IE00B12V2V27.USD","LU0359201612.USD","BK4548","LU0359202008.SGD","BK4552","SRC","BK4535","SD","PR","BK4533","BK4563","BK4023","IE00BYTNYN87.SGD","TME","LU1023057109.AUD","BK4565","BK4509","LU1169590202.USD","BK4007","BK4121","IE00BFXG0V08.USD","LU2413666699.HKD","BK4181","PD","BK4526","BK4136","BK4231","IE00BYQQ9H92.USD","SON","LU1169589451.USD"],"gpt_icon":0},{"id":"2523945783","title":"iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of  Zio® Long-Term Continuous Monitoring for Arrhythmia Detection","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945783","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945783?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:05","pubTimestamp":1743422700,"startTime":"0","endTime":"0","summary":"Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052252/0/en/iRhythm-Unveils-New-Real-World-Data-at-ACC-25-Demonstrating-the-Benefits-of-Zio-Long-Term-Continuous-Monitoring-for-Arrhythmia-Detection.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4080","SRC","FL","IRTC","BK4006","BK4231","BK4094","BK4082","BK4563","HCC"],"gpt_icon":0},{"id":"2523503016","title":"Singapore Red Cross pledges S$150,000 to support Myanmar, Thailand quake relief","url":"https://stock-news.laohu8.com/highlight/detail?id=2523503016","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523503016?lang=en_us&edition=fundamental","pubTime":"2025-03-29 08:56","pubTimestamp":1743209760,"startTime":"0","endTime":"0","summary":"A public fundraising appeal will also be launched soon.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--hQ5CXeoj--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_one-cms:core:watermark:ap_data-1,w_0.1/f_auto,q_auto/v1/one-cms/core/thailand_earthquake_69186.jpg?itok=Bt13cK7F","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--hQ5CXeoj--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_one-cms:core:watermark:ap_data-1,w_0.1/f_auto,q_auto/v1/one-cms/core/thailand_earthquake_69186.jpg?itok=Bt13cK7F"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/earthquake-myanmar-thailand-red-cross-150-000-fundraising-5031866","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4231","BK4080","RFL","SRC","BK4205","BK4233"],"gpt_icon":0},{"id":"2522234805","title":"Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2522234805","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522234805?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:05","pubTimestamp":1742994300,"startTime":"0","endTime":"0","summary":"SON-1010 is being studied as a combination therapy with trabectedin (Yondelis), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/26/3049745/0/en/Sonnet-BioTherapeutics-Successfully-Completes-First-Safety-Review-of-SON-1010-in-Combination-with-Trabectedin-in-Certain-Sarcomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4585","01698","IE00BYQNZ168.SGD","LU1023057109.AUD","LU0359201612.USD","SON","BK4571","SRC","BK4080","BK4588","BK4139","BK4552","LU2413666699.HKD","IE00BYTNYN87.SGD","PR","BK4213","BK4548","BK4007","IE00B12V2V27.USD","BK4195","BK4218","PK","BK4023","BK4526","BK4563","PROC","BK4211","SONN","IE00BYQQ9H92.USD","LU0359202008.SGD","BK4108","BK4509","IE00BFXG0V08.USD","LU2413666426.HKD","MTD","BK4567","PD","BK4181","PFS","LU1721428933.USD","LU2039709279.SGD","SG9999011746.SGD","BK4121","BK4531","LU1093756168.USD","BK4231","LU0347712357.USD","BK4136"],"gpt_icon":1},{"id":"2519558835","title":"TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519558835","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519558835?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:47","pubTimestamp":1741866420,"startTime":"0","endTime":"0","summary":"Clinical trial Safety Review Committee  approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3. No significant safety or dose limiting toxicities reported in Cohorts 1, 2, or 3. Patients currently being evaluated for Cohort 4 eligibility. \"SRC approval to open the fourth cohort and expand enrollment in Cohort 3 is an important advancement for the clinical trial. It will provide an opportunity to obtain additional safety and PK/PD data, inform the dose expansion stage of the clinical trial and may allow us to obtain initial evidence of clinical activity\" commented Sue Duggan, TransCode's Senior Vice President of Operations. Duggan added, \"Enrollment into the study continues based on the cumulative safety data review. Eligible subjects may now be screened and scheduled in Cohort 4 for treatment with the next dose level of TTX-MC138","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-safety-review-114700704.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transcode-therapeutics-announces-safety-review-114700704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1169590202.USD","PK","BK4181","RNAZ","SRC","BK4231","BK4539","BK4218","PD","LENZ","LU1169589451.USD","BK4080","BK4023"],"gpt_icon":0},{"id":"2517261912","title":"SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517261912","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517261912?lang=en_us&edition=fundamental","pubTime":"2025-03-05 21:44","pubTimestamp":1741182240,"startTime":"0","endTime":"0","summary":"Safety Review Committee  meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase  of the SECuRE study.Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, theSRC confirmed expansion at 8 GBq dose level and recommended to increase the number of cycles from up to 4 to up to 6.Cohort 4 of the Dose Escalation Phase of theSECuRE trial, assessing multiple administrations of 67Cu-SAR-bisPSMA, is complete. Prostate-specific antigen  levels are continuing to drop in 3 participants,with reductions ≥80% observed in 3 cases so far. A complete response was achieved in a participant in cohort 4 following 2 doses of 12 GBq of 67Cu-SAR-bisPSMA to date, based on the Response Evaluation Criteria in Solid Tumors v1.1 .Across all cohorts, 68% of participants have shown reductions inPSA levels, despite the vast majority of the participants (77%) only receiving a single dose of 67Cu-SAR-bisPSMA. The majority of part","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/secure-trial-92-pre-chemo-134400223.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/secure-trial-92-pre-chemo-134400223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4135","BK4213","TGA","SAR.AU","SAR","PSA","BK4533","BK7095","BK4084","DLT.AU","BK4217","CU6.AU","SRC","ADT","BK7001","BK7142","BK4165","BK7096","RLT.AU","BK4080","BK4588","BK4192","BK7084","BK4231","TGA.AU","ADT.AU","BK4585"],"gpt_icon":0},{"id":"2517195715","title":"Why Appen, Clarity, Qantas, and Resolute shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195715","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517195715?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:25","pubTimestamp":1741141539,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having another tough session on Wednesday. In afternoon trade, the benchmark index is down a disappointing 1.2% to 8,099.7 points. Four ASX shares that have not let ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/05/why-appen-clarity-qantas-and-resolute-shares-are-pushing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7506","BK7096","BK4231","BK7030","CU6.AU","XJO.AU","RSG.AU","APX.AU","BK7104","SRC","BK7503","BK4080","BK7061","QAN.AU"],"gpt_icon":1},{"id":"2517954233","title":"Guess which ASX 200 biotech stock is jumping 7% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2517954233","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517954233?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:30","pubTimestamp":1741131012,"startTime":"0","endTime":"0","summary":"The Clarity Pharmaceuticals Ltd  share price is avoiding the market weakness on Wednesday. In morning trade, the ASX 200 biotech stock is up 7% to $3.18. Why is this ASX 200 biotech stock jumping?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/05/guess-which-asx-200-biotech-stock-is-jumping-7-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","XJO.AU","BK7096","BK4231","SRC","XKO.AU","CU6.AU","BK4080"],"gpt_icon":0},{"id":"2510378171","title":"INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2510378171","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510378171?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:00","pubTimestamp":1739361600,"startTime":"0","endTime":"0","summary":"Medical review of Phase 1 cohorts demonstrated no safety issues. The Scientific Review Committee  charter is to review the safety data from the patients treated in the Phase I portion of the trial as required by the FDA. Yesterday, the SRC held the third meeting evaluating the safety in INKmune therapy in men with mCRPC. The SRC unanimously voted to open all Phase II cohorts of the CaRePC trial to enrollment.Mark Lowdell, CSO of INMB and inventor of INKmune, has been invited to speak at the 10th Annual Innate Killer Summit in San Diego on March 4th on the use of INKmune to treat men with mCRPC in the CaRe PC trial. The trial has a Bayesian design with three ascending dose cohorts. Now that the initial three patients in each cohort have passed medical review, there is a six patient Phase II extension at the two higher dose levels. Patient recruitment continues to meet expectations.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inmune-bio-opens-phase-ii-120000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INMB","BK4231","SRC","BK4080","BK4139"],"gpt_icon":0},{"id":"2510390787","title":"Island completes dosing in phase 2b arm of mosquito-borne dengue trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2510390787","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510390787?lang=en_us&edition=fundamental","pubTime":"2025-02-12 12:18","pubTimestamp":1739333931,"startTime":"0","endTime":"0","summary":"Island completes phase 2b therapeutic arm of PROTECT clinical trial of ISLA-101 for treatment of dengue fever. Phase 2b follows promising results in the phase 2a arm and favourable SRC review observing anti-viral activity in ISLA-101-treated subjects. High-level results of phase 2b trial anticipated in the next six to eight weeks","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/02/2025-2-12-ILA-NM-1-640x359.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/02/2025-2-12-ILA-NM-1-640x359.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/island-completes-dosing-in-phase-2b-arm-of-mosquito-borne-dengue-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4231","BK4080","SRC"],"gpt_icon":0},{"id":"2509961718","title":"SigmaRoc: Strong Market Position, Decarbonization Success, and Undervalued Investment Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2509961718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509961718?lang=en_us&edition=fundamental","pubTime":"2025-02-07 17:46","pubTimestamp":1738921592,"startTime":"0","endTime":"0","summary":"Charlie Campbell, an analyst from Stifel Nicolaus, has initiated a new Buy rating on SigmaRoc (SRC). Charlie Campbell’s rating is based on SigmaRoc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sigmaroc-strong-market-position-decarbonization-success-and-undervalued-investment-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sigmaroc-strong-market-position-decarbonization-success-and-undervalued-investment-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4231","BK4080","SRC"],"gpt_icon":0},{"id":"2509402104","title":"Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509402104","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509402104?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:59","pubTimestamp":1738756740,"startTime":"0","endTime":"0","summary":"SRC recommended that the trial escalate to the next dose level of 22mg capsule. “As we are observing substantial exposure levels of PAS-004, we remain encouraged by the safety profile PAS-004 continues to exhibit,” stated Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. “With the differentiated profile of PAS-004, we believe it is possible that this highly specific macrocyclic MEK inhibitor with a half life of greater than 60 hours may change the treatment paradigm for patients with NF1 and inoperable plexiform neurofibromas. We are looking forward to presenting updated pharmakokinetic  and pharmacodynamic  data during Q1 2025.”This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial and the saf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-positive-safety-115900013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KTTA","IE0031619046.USD","AE","KTTAW","LENZ","BK4135","BK4080","BK4139","BK4157","IE00B66KJ199.SGD","BK4231","IE00B19Z4B17.USD","SRC","PD","BK4181","LU1169590202.USD","LU1169589451.USD","BK4023","BK4218","PK","IE00B7SZL793.SGD","BK4138","AEIS","CNS"],"gpt_icon":1},{"id":"2507952602","title":"Realty Income Announces 2024 Dividend Tax Allocation for Realty Income Corporation and Spirit Realty Capital, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2507952602","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507952602?lang=en_us&edition=fundamental","pubTime":"2025-01-29 05:05","pubTimestamp":1738098300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 28, 2025 /PRNewswire/ -- Realty Income Corporation , The Monthly Dividend Company, today announced the final calculation of the dividend tax status for its 2024 common stock distributions, and for its 2024 6.00% Series A Cumulative Redeemable Preferred Stock  distributions, which were redeemed in full on September 30, 2024. Additionally, Realty Income announced today the final calculation of the dividend tax status for Spirit Realty Capital, Inc.'s  2024 common stock distributions. A portion of the Realty Income common stock distributions are considered a non-taxable distribution, whereas Spirit Realty Capital's final common stock distribution is fully a non-taxable distribution. Respective tax attributes of the distributions paid per share are outlined below:. Total Series A Preferred Stock Distributions Paid in 2024. Shareholders are encouraged to consult with their tax advisors as to their specific tax treatment of any Realty Income common or preferred stock dividend","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/realty-income-announces-2024-dividend-210500412.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/realty-income-announces-2024-dividend-210500412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","O","BK4588","BK4231","SRC","BK4080"],"gpt_icon":0},{"id":"2505755157","title":"Island completes phase 2b enrolments in dengue fever trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505755157","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505755157?lang=en_us&edition=fundamental","pubTime":"2025-01-22 10:26","pubTimestamp":1737512775,"startTime":"0","endTime":"0","summary":"All subjects enrolled in Island Pharmaceutical’s phase 2b arm of phase 2a/b PROTECT trial of ISLA-101 in dengue fever. Phase 2b study will explore ability of ISLA-101 to reduce symptoms of a person already infected with dengue virus. High-level results expected around April 2025 with full unblinded study results from phase 2a/b expected in Q4 FY25","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-22-ILA-NM-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/01/2025-1-22-ILA-NM-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/health/island-completes-phase-2b-enrolments-in-dengue-fever-trial/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4080","SRC","BK4231"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SRC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-01-23","symbol":"SRC","reason":null,"defaultRemindTime":1706020200000,"announcedDate":"2024-01-10","type":"delisting","dateTimestamp":1705986000000},{"date":"2023-12-27","symbol":"SRC","amount":0.6696,"announcedDate":"2023-11-28","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"Spirit Realty Capital","recordDate":"2024-01-12","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2024-01-12"},{"market":"US","date":"2023-11-02","symbol":"SRC","fiscalQuarterEnding":"2023/09","expectedEps":0.86,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1698897600000,"reportTimeType":"pre","actualEps":0.92},{"date":"2023-09-28","symbol":"SRC","amount":0.6696,"announcedDate":"2023-08-09","type":"dividend","market":"US","newRecordDate":"2023-09-29","defaultRemindTime":1695907800000,"name":"Spirit Realty Capital","recordDate":"2023-10-13","payableDate":"2023-09-29","currency":"USD","dateTimestamp":1695873600000,"payDate":"2023-10-13"},{"market":"US","date":"2023-08-07","symbol":"SRC","fiscalQuarterEnding":"2023/06","expectedEps":0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1691380800000,"reportTimeType":"post","actualEps":0.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SRC\",market:\"US\",,,undefined,":[{"executeDate":"2017-03-29","recordDate":"2017-03-31","paymentDate":"2017-04-14","value":0.18,"currency":"USD"},{"executeDate":"2017-06-28","recordDate":"2017-06-30","paymentDate":"2017-07-14","value":0.18,"currency":"USD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-13","value":0.18,"currency":"USD"},{"executeDate":"2017-12-28","recordDate":"2017-12-29","paymentDate":"2018-01-12","value":0.18,"currency":"USD"},{"executeDate":"2018-03-28","recordDate":"2018-03-30","paymentDate":"2018-04-13","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SRC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1429,"buy":0.0714,"hold":0.7857,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.7857,"analysts":14,"updateTime":1699678800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SRC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SRC","date":"2024-01-23","current":23.132655,"percent":0.299677,"low":11.974037,"twenty":21.77699,"median":25.699054,"eighty":47.920767,"high":2180.914394,"avg":155.68251,"sd":460.537211,"marketCap":5989090759},"quantilePoints":[{"date":"2020-05-08","current":26.54342,"twenty":-93.997436,"median":26.475166,"eighty":41.659269,"marketCap":3074816366},{"date":"2020-05-15","current":23.228825,"twenty":-93.810003,"median":26.475166,"eighty":41.659269,"marketCap":2690850345},{"date":"2020-05-22","current":25.29045,"twenty":-93.609189,"median":26.475166,"eighty":41.659269,"marketCap":2929671033},{"date":"2020-05-29","current":25.263791,"twenty":-93.35014,"median":26.481687,"eighty":41.659269,"marketCap":2926582835},{"date":"2020-06-05","current":33.19927,"twenty":-92.966557,"median":26.536805,"eighty":41.659269,"marketCap":3845836606},{"date":"2020-06-12","current":30.853283,"twenty":-92.87284,"median":26.61547,"eighty":41.659269,"marketCap":3574075133},{"date":"2020-06-19","current":31.750801,"twenty":-92.685408,"median":26.687479,"eighty":41.659269,"marketCap":3678044484},{"date":"2020-06-26","current":30.551148,"twenty":-92.055771,"median":26.771857,"eighty":41.659269,"marketCap":3539075549},{"date":"2020-07-02","current":30.435626,"twenty":-92.055771,"median":26.827299,"eighty":41.659269,"marketCap":3525693356},{"date":"2020-07-10","current":28.756113,"twenty":-91.748245,"median":26.880343,"eighty":41.659269,"marketCap":3331136846},{"date":"2020-07-17","current":30.382308,"twenty":-91.581806,"median":26.967004,"eighty":41.659269,"marketCap":3519516958},{"date":"2020-07-24","current":28.987157,"twenty":-91.172425,"median":27.000883,"eighty":41.659269,"marketCap":3357901234},{"date":"2020-07-31","current":50.951563,"twenty":-90.831904,"median":27.183235,"eighty":41.707972,"marketCap":3550865398},{"date":"2020-08-07","current":52.23792,"twenty":-90.248784,"median":27.464856,"eighty":41.920968,"marketCap":3640512899},{"date":"2020-08-14","current":52.903277,"twenty":-89.993422,"median":27.592346,"eighty":42.086263,"marketCap":3686882296},{"date":"2020-08-21","current":52.163992,"twenty":-89.613313,"median":27.902363,"eighty":42.245568,"marketCap":3635360744},{"date":"2020-08-28","current":53.731277,"twenty":-89.050887,"median":28.030598,"eighty":42.353314,"marketCap":3744586435},{"date":"2020-09-04","current":53.923491,"twenty":-88.287296,"median":28.249351,"eighty":42.410344,"marketCap":3757982039},{"date":"2020-09-11","current":53.524277,"twenty":-88.154584,"median":28.460561,"eighty":42.475124,"marketCap":3730160401},{"date":"2020-09-18","current":52.784992,"twenty":-88.001027,"median":28.746196,"eighty":42.534926,"marketCap":3678638848},{"date":"2020-09-25","current":50.315778,"twenty":-87.024944,"median":28.859221,"eighty":42.725691,"marketCap":3506556863},{"date":"2020-10-02","current":52.784992,"twenty":-86.762538,"median":29.064019,"eighty":42.777357,"marketCap":3678638848},{"date":"2020-10-09","current":51.321206,"twenty":13.104171,"median":29.31595,"eighty":42.859575,"marketCap":3576626174},{"date":"2020-10-16","current":47.979635,"twenty":14.494025,"median":29.546785,"eighty":42.940728,"marketCap":3343748757},{"date":"2020-10-23","current":49.768706,"twenty":15.048563,"median":29.688076,"eighty":43.018204,"marketCap":3468430914},{"date":"2020-10-30","current":44.431064,"twenty":15.276158,"median":29.871143,"eighty":43.068933,"marketCap":3096445305},{"date":"2020-11-06","current":1514.980316,"twenty":15.709562,"median":30.009083,"eighty":43.17951,"marketCap":3325381794},{"date":"2020-11-13","current":1803.901979,"twenty":16.645311,"median":30.127612,"eighty":43.263013,"marketCap":3959564845},{"date":"2020-11-20","current":1764.255782,"twenty":17.947113,"median":30.382308,"eighty":43.333315,"marketCap":3872541442},{"date":"2020-11-27","current":1871.300515,"twenty":21.225642,"median":30.527403,"eighty":43.417649,"marketCap":4107504631},{"date":"2020-12-04","current":2036.214107,"twenty":21.623279,"median":30.791079,"eighty":43.486526,"marketCap":4469489965},{"date":"2020-12-11","current":2090.867093,"twenty":21.778606,"median":30.951032,"eighty":43.62088,"marketCap":4589453270},{"date":"2020-12-18","current":2091.387598,"twenty":21.870027,"median":31.395348,"eighty":43.74382,"marketCap":4590595777},{"date":"2020-12-24","current":2097.113149,"twenty":21.936595,"median":31.875209,"eighty":43.806946,"marketCap":4603163362},{"date":"2020-12-31","current":2090.867093,"twenty":22.059969,"median":32.941567,"eighty":43.929815,"marketCap":4589453270},{"date":"2021-01-08","current":2003.422316,"twenty":22.346658,"median":34.450941,"eighty":43.978577,"marketCap":4397511983},{"date":"2021-01-15","current":1987.286672,"twenty":22.499322,"median":35.307705,"eighty":44.086589,"marketCap":4362094245},{"date":"2021-01-22","current":2066.403376,"twenty":22.706129,"median":35.84882,"eighty":44.134242,"marketCap":4535755410},{"date":"2021-01-29","current":2007.065848,"twenty":22.853468,"median":36.261669,"eighty":44.247898,"marketCap":4405509536},{"date":"2021-02-05","current":2086.182552,"twenty":23.100216,"median":36.657717,"eighty":44.326702,"marketCap":4579170701},{"date":"2021-02-12","current":2145.520079,"twenty":23.286608,"median":36.79577,"eighty":44.366344,"marketCap":4709416574},{"date":"2021-02-19","current":184.197094,"twenty":23.35939,"median":36.931048,"eighty":44.406964,"marketCap":4919535990},{"date":"2021-02-26","current":185.014219,"twenty":23.466787,"median":37.055826,"eighty":44.537229,"marketCap":4941359755},{"date":"2021-03-05","current":178.864281,"twenty":23.544894,"median":37.12062,"eighty":44.646862,"marketCap":4777107211},{"date":"2021-03-12","current":184.326114,"twenty":23.649571,"median":37.201605,"eighty":44.741227,"marketCap":4922981848},{"date":"2021-03-19","current":179.896438,"twenty":23.76334,"median":37.267154,"eighty":45.068895,"marketCap":4804674071},{"date":"2021-03-26","current":185.659317,"twenty":23.855579,"median":37.309462,"eighty":45.145403,"marketCap":4958589043},{"date":"2021-04-01","current":186.863501,"twenty":23.974367,"median":37.362574,"eighty":45.33813,"marketCap":4990750380},{"date":"2021-04-09","current":188.669776,"twenty":24.033695,"median":37.482017,"eighty":45.49559,"marketCap":5038992386},{"date":"2021-04-16","current":190.734091,"twenty":24.170556,"median":37.517255,"eighty":45.728304,"marketCap":5094126107},{"date":"2021-04-23","current":197.787167,"twenty":24.300666,"median":37.561888,"eighty":46.08352,"marketCap":5282499654},{"date":"2021-04-30","current":204.453184,"twenty":24.376499,"median":37.577713,"eighty":46.298453,"marketCap":5460535629},{"date":"2021-05-07","current":132.237039,"twenty":24.536847,"median":37.652534,"eighty":46.41481,"marketCap":5433090981},{"date":"2021-05-14","current":128.487618,"twenty":24.584413,"median":37.71081,"eighty":46.484624,"marketCap":5279042274},{"date":"2021-05-21","current":128.925556,"twenty":24.636739,"median":37.832905,"eighty":46.787152,"marketCap":5297035392},{"date":"2021-05-28","current":132.227035,"twenty":24.751207,"median":37.867956,"eighty":46.996595,"marketCap":5432679961},{"date":"2021-06-04","current":138.438292,"twenty":24.770977,"median":37.888273,"eighty":47.920492,"marketCap":5687875677},{"date":"2021-06-11","current":142.355301,"twenty":24.827339,"median":37.94667,"eighty":48.902994,"marketCap":5848809912},{"date":"2021-06-18","current":133.430116,"twenty":24.902133,"median":37.998298,"eighty":49.593837,"marketCap":5482109762},{"date":"2021-06-25","current":136.675638,"twenty":24.963422,"median":38.049927,"eighty":49.839678,"marketCap":5615455271},{"date":"2021-07-02","current":134.269475,"twenty":25.019346,"median":38.05837,"eighty":50.279896,"marketCap":5516595669},{"date":"2021-07-09","current":136.283937,"twenty":25.087824,"median":38.065735,"eighty":51.223621,"marketCap":5599361847},{"date":"2021-07-16","current":135.696386,"twenty":25.161407,"median":38.153183,"eighty":51.578478,"marketCap":5575221712},{"date":"2021-07-23","current":139.949139,"twenty":25.274023,"median":38.238741,"eighty":51.995435,"marketCap":5749950310},{"date":"2021-07-30","current":140.508711,"twenty":25.379375,"median":38.256439,"eighty":52.492234,"marketCap":5772940915},{"date":"2021-08-06","current":47.126902,"twenty":25.419415,"median":38.331929,"eighty":52.634177,"marketCap":6099304983},{"date":"2021-08-13","current":46.841619,"twenty":25.506579,"median":38.393809,"eighty":52.601649,"marketCap":6062382809},{"date":"2021-08-20","current":45.580852,"twenty":25.567588,"median":38.428701,"eighty":52.601649,"marketCap":5899210619},{"date":"2021-08-27","current":46.952051,"twenty":25.682178,"median":38.565058,"eighty":52.601649,"marketCap":6076675263},{"date":"2021-09-03","current":47.8079,"twenty":25.731746,"median":38.769257,"eighty":52.601649,"marketCap":6187441786},{"date":"2021-09-10","current":45.507231,"twenty":25.767762,"median":38.841996,"eighty":52.601649,"marketCap":5889682316},{"date":"2021-09-17","current":45.442812,"twenty":25.854339,"median":38.921369,"eighty":52.601649,"marketCap":5881345051},{"date":"2021-09-24","current":44.991881,"twenty":25.875526,"median":39.185745,"eighty":52.601649,"marketCap":5822984195},{"date":"2021-10-01","current":43.61148,"twenty":25.926473,"median":39.318072,"eighty":52.601649,"marketCap":5644328513},{"date":"2021-10-08","current":43.445831,"twenty":25.936015,"median":39.366062,"eighty":52.480406,"marketCap":5622889831},{"date":"2021-10-15","current":44.264869,"twenty":25.941955,"median":39.542896,"eighty":52.368034,"marketCap":5728892202},{"date":"2021-10-22","current":44.807827,"twenty":25.946911,"median":39.59877,"eighty":52.246792,"marketCap":5799163437},{"date":"2021-10-29","current":45.028692,"twenty":25.95304,"median":39.779469,"eighty":52.208349,"marketCap":5827748346},{"date":"2021-11-05","current":38.774704,"twenty":25.955541,"median":39.584452,"eighty":52.193563,"marketCap":6068357526},{"date":"2021-11-12","current":38.112832,"twenty":25.955541,"median":39.34367,"eighty":52.193563,"marketCap":5964772476},{"date":"2021-11-19","current":36.891519,"twenty":25.955541,"median":39.185745,"eighty":52.193563,"marketCap":5773633395},{"date":"2021-11-26","current":35.851433,"twenty":25.955541,"median":39.121399,"eighty":52.193563,"marketCap":5610856888},{"date":"2021-12-03","current":35.236837,"twenty":25.955541,"median":38.915134,"eighty":52.193563,"marketCap":5514670769},{"date":"2021-12-10","current":37.072746,"twenty":25.955541,"median":38.813951,"eighty":52.193563,"marketCap":5801995968},{"date":"2021-12-17","current":36.300561,"twenty":25.955541,"median":38.721092,"eighty":52.193563,"marketCap":5681146743},{"date":"2021-12-23","current":37.143661,"twenty":25.955541,"median":38.621326,"eighty":52.193563,"marketCap":5813094367},{"date":"2021-12-31","current":37.971002,"twenty":25.955541,"median":38.465026,"eighty":52.193563,"marketCap":5942575679},{"date":"2022-01-07","current":37.986761,"twenty":25.958043,"median":38.424681,"eighty":52.178778,"marketCap":5945041990},{"date":"2022-01-14","current":40.479343,"twenty":25.958043,"median":38.411323,"eighty":52.178778,"marketCap":6335138658},{"date":"2022-01-21","current":37.231857,"twenty":25.958043,"median":38.390333,"eighty":52.178778,"marketCap":5826897339},{"date":"2022-01-28","current":38.251796,"twenty":25.958043,"median":38.332389,"eighty":52.178778,"marketCap":5986520869},{"date":"2022-02-04","current":37.01971,"twenty":25.958043,"median":38.318497,"eighty":52.178778,"marketCap":5793695644},{"date":"2022-02-11","current":37.501121,"twenty":25.958043,"median":38.254117,"eighty":52.178778,"marketCap":5869037951},{"date":"2022-02-18","current":34.819069,"twenty":25.958043,"median":38.240969,"eighty":52.178778,"marketCap":5978503814},{"date":"2022-02-25","current":34.804189,"twenty":25.958043,"median":38.215079,"eighty":52.178778,"marketCap":5975948898},{"date":"2022-03-04","current":35.272907,"twenty":25.958043,"median":38.146473,"eighty":52.178778,"marketCap":6056428757},{"date":"2022-03-11","current":34.56611,"twenty":25.958043,"median":38.085254,"eighty":52.178778,"marketCap":5935070239},{"date":"2022-03-18","current":34.335471,"twenty":25.958043,"median":38.065735,"eighty":52.178778,"marketCap":5895469039},{"date":"2022-03-25","current":34.208991,"twenty":25.958043,"median":38.049927,"eighty":52.178778,"marketCap":5873752251},{"date":"2022-04-01","current":34.819069,"twenty":25.958043,"median":38.027704,"eighty":52.178778,"marketCap":5978503814},{"date":"2022-04-08","current":34.157274,"twenty":25.958043,"median":37.977004,"eighty":52.178778,"marketCap":5864872207},{"date":"2022-04-14","current":34.231674,"twenty":25.958043,"median":37.947139,"eighty":52.178778,"marketCap":5877646923},{"date":"2022-04-22","current":34.291195,"twenty":25.958043,"median":37.91384,"eighty":52.178778,"marketCap":5887866696},{"date":"2022-04-29","current":32.327021,"twenty":25.958043,"median":37.872977,"eighty":52.178778,"marketCap":5550614188},{"date":"2022-05-06","current":24.292186,"twenty":25.931441,"median":37.847879,"eighty":52.178778,"marketCap":5568424854},{"date":"2022-05-13","current":24.6203,"twenty":25.875816,"median":37.793325,"eighty":52.178778,"marketCap":5643637539},{"date":"2022-05-20","current":23.805873,"twenty":25.858744,"median":37.793325,"eighty":52.178778,"marketCap":5456948910},{"date":"2022-05-27","current":24.678892,"twenty":25.770173,"median":37.782901,"eighty":52.178778,"marketCap":5657068375},{"date":"2022-06-03","current":24.380074,"twenty":25.738237,"median":37.748948,"eighty":52.178778,"marketCap":5588571109},{"date":"2022-06-10","current":23.173081,"twenty":25.689411,"median":37.691197,"eighty":52.178778,"marketCap":5311895875},{"date":"2022-06-17","current":21.632115,"twenty":25.601375,"median":37.652534,"eighty":52.178778,"marketCap":4958664872},{"date":"2022-06-24","current":22.53443,"twenty":25.542353,"median":37.577713,"eighty":52.193563,"marketCap":5165499756},{"date":"2022-07-01","current":22.809812,"twenty":25.47244,"median":37.561888,"eighty":52.193563,"marketCap":5228624688},{"date":"2022-07-08","current":23.290265,"twenty":25.403817,"median":37.533347,"eighty":52.193563,"marketCap":5338757548},{"date":"2022-07-15","current":24.239453,"twenty":25.337902,"median":37.509281,"eighty":52.193563,"marketCap":5556337101},{"date":"2022-07-22","current":25.083176,"twenty":25.254824,"median":37.472162,"eighty":52.193563,"marketCap":5749741148},{"date":"2022-07-29","current":25.979631,"twenty":25.187885,"median":37.336884,"eighty":52.193563,"marketCap":5955232948},{"date":"2022-08-05","current":25.912119,"twenty":25.170969,"median":37.272951,"eighty":52.193563,"marketCap":5805428947},{"date":"2022-08-12","current":27.220505,"twenty":25.170969,"median":37.246094,"eighty":52.193563,"marketCap":6098563570},{"date":"2022-08-19","current":25.97906,"twenty":25.170969,"median":37.201605,"eighty":52.193563,"marketCap":5820426532},{"date":"2022-08-26","current":25.516561,"twenty":25.170969,"median":37.156512,"eighty":52.193563,"marketCap":5716806852},{"date":"2022-09-02","current":24.439425,"twenty":25.137956,"median":37.11142,"eighty":52.193563,"marketCap":5475482069},{"date":"2022-09-09","current":25.321824,"twenty":25.093166,"median":37.072746,"eighty":52.193563,"marketCap":5673177512},{"date":"2022-09-16","current":25.638271,"twenty":25.087615,"median":37.021234,"eighty":52.193563,"marketCap":5744075189},{"date":"2022-09-23","current":23.331861,"twenty":25.064167,"median":36.930916,"eighty":52.193563,"marketCap":5227340202},{"date":"2022-09-30","current":22.005219,"twenty":25.007629,"median":36.79577,"eighty":52.193563,"marketCap":4930115329},{"date":"2022-10-07","current":21.518378,"twenty":24.962383,"median":36.660491,"eighty":52.193563,"marketCap":4821041981},{"date":"2022-10-14","current":21.475779,"twenty":24.922679,"median":36.48012,"eighty":52.193563,"marketCap":4811498063},{"date":"2022-10-21","current":21.512293,"twenty":24.858503,"median":36.221767,"eighty":52.193563,"marketCap":4819678564},{"date":"2022-10-28","current":23.362289,"twenty":24.827339,"median":35.972732,"eighty":52.193563,"marketCap":5234157287},{"date":"2022-11-04","current":23.25275,"twenty":24.773188,"median":35.585763,"eighty":52.193563,"marketCap":5209615783},{"date":"2022-11-11","current":21.599078,"twenty":24.752915,"median":35.307705,"eighty":52.193563,"marketCap":5611548483},{"date":"2022-11-18","current":22.13126,"twenty":24.730614,"median":35.1468,"eighty":52.193563,"marketCap":5749812121},{"date":"2022-11-25","current":22.389288,"twenty":24.643741,"median":34.819069,"eighty":52.193563,"marketCap":5816849037},{"date":"2022-12-02","current":22.174265,"twenty":24.613224,"median":34.65539,"eighty":52.193563,"marketCap":5760984941},{"date":"2022-12-09","current":22.195767,"twenty":24.573379,"median":34.541127,"eighty":52.193563,"marketCap":5766571350},{"date":"2022-12-16","current":21.867857,"twenty":24.543146,"median":34.417376,"eighty":52.193563,"marketCap":5681378603},{"date":"2022-12-23","current":21.916237,"twenty":24.446405,"median":34.275951,"eighty":52.193563,"marketCap":5693948025},{"date":"2022-12-30","current":21.464689,"twenty":24.380422,"median":34.231674,"eighty":52.193563,"marketCap":5576633423},{"date":"2023-01-06","current":21.760345,"twenty":24.359795,"median":34.142394,"eighty":51.862363,"marketCap":5653446555},{"date":"2023-01-13","current":22.684945,"twenty":24.292288,"median":34.037872,"eighty":51.436535,"marketCap":5893662170},{"date":"2023-01-20","current":22.201143,"twenty":24.227194,"median":33.993593,"eighty":50.924949,"marketCap":5767967953},{"date":"2023-01-27","current":23.05586,"twenty":24.158963,"median":33.821312,"eighty":49.833763,"marketCap":5990027736},{"date":"2023-02-03","current":23.319264,"twenty":24.035772,"median":33.569154,"eighty":49.526221,"marketCap":6058461254},{"date":"2023-02-10","current":23.668676,"twenty":23.978638,"median":33.003771,"eighty":48.325621,"marketCap":6149240411},{"date":"2023-02-17","current":23.760061,"twenty":23.932079,"median":31.884095,"eighty":47.733513,"marketCap":6172982652},{"date":"2023-02-24","current":22.87309,"twenty":23.84205,"median":31.670824,"eighty":47.598078,"marketCap":5942543254},{"date":"2023-03-03","current":20.736687,"twenty":23.798842,"median":30.977691,"eighty":47.598078,"marketCap":5920655868},{"date":"2023-03-10","current":19.479618,"twenty":23.754148,"median":30.853283,"eighty":47.598078,"marketCap":5561742600},{"date":"2023-03-17","current":19.167825,"twenty":23.71176,"median":30.554606,"eighty":47.598078,"marketCap":5472720806},{"date":"2023-03-24","current":18.895563,"twenty":23.637539,"median":30.435626,"eighty":47.598078,"marketCap":5394985612},{"date":"2023-03-31","current":19.717109,"twenty":23.607162,"median":30.200139,"eighty":47.583354,"marketCap":5629550204},{"date":"2023-04-06","current":19.197457,"twenty":23.544654,"median":30.039518,"eighty":47.583354,"marketCap":5481181035},{"date":"2023-04-14","current":18.984646,"twenty":23.490752,"median":29.961662,"eighty":47.598078,"marketCap":5420420327},{"date":"2023-04-21","current":18.776785,"twenty":23.446835,"median":29.795711,"eighty":47.598078,"marketCap":5361072659},{"date":"2023-04-28","current":18.658008,"twenty":23.389146,"median":29.57505,"eighty":47.598078,"marketCap":5327159706},{"date":"2023-05-05","current":16.805477,"twenty":23.336129,"median":29.387041,"eighty":47.598078,"marketCap":5472417898},{"date":"2023-05-12","current":16.68832,"twenty":23.314814,"median":29.262633,"eighty":47.627527,"marketCap":5434267812},{"date":"2023-05-19","current":16.666625,"twenty":23.281907,"median":28.987157,"eighty":47.627527,"marketCap":5427202982},{"date":"2023-05-26","current":16.414955,"twenty":23.207241,"median":28.852809,"eighty":47.627527,"marketCap":5345250945},{"date":"2023-06-02","current":16.74039,"twenty":23.145644,"median":28.73834,"eighty":47.627527,"marketCap":5451223406},{"date":"2023-06-09","current":17.248069,"twenty":23.092708,"median":28.45223,"eighty":47.627527,"marketCap":5616540446},{"date":"2023-06-16","current":17.369565,"twenty":22.98083,"median":28.181067,"eighty":47.627527,"marketCap":5656103498},{"date":"2023-06-22","current":16.93999,"twenty":22.950432,"median":28.000425,"eighty":47.642251,"marketCap":5516219849},{"date":"2023-06-30","current":17.04413,"twenty":22.860626,"median":27.902363,"eighty":47.658919,"marketCap":5550131037},{"date":"2023-07-07","current":17.096199,"twenty":22.819497,"median":27.713783,"eighty":47.667253,"marketCap":5567086631},{"date":"2023-07-14","current":17.690661,"twenty":22.781974,"median":27.511978,"eighty":47.675587,"marketCap":5760662993},{"date":"2023-07-19","current":17.786122,"twenty":22.720474,"median":27.355963,"eighty":47.675587,"marketCap":5791748248},{"date":"2023-07-28","current":17.573504,"twenty":22.679408,"median":27.156228,"eighty":47.708717,"marketCap":5722512907},{"date":"2023-08-04","current":16.987721,"twenty":22.594109,"median":27.00691,"eighty":47.708717,"marketCap":5531762477},{"date":"2023-08-11","current":18.910849,"twenty":22.487052,"median":26.968876,"eighty":47.708717,"marketCap":5617921480},{"date":"2023-08-18","current":17.992662,"twenty":22.38232,"median":26.902938,"eighty":47.708717,"marketCap":5345151959},{"date":"2023-08-25","current":18.268594,"twenty":22.358559,"median":26.838753,"eighty":47.708717,"marketCap":5427124147},{"date":"2023-09-01","current":18.3685,"twenty":22.31833,"median":26.767597,"eighty":47.708717,"marketCap":5456803732},{"date":"2023-09-08","current":17.88324,"twenty":22.243073,"median":26.695235,"eighty":47.708717,"marketCap":5312645747},{"date":"2023-09-15","current":17.559734,"twenty":22.194692,"median":26.633237,"eighty":47.708717,"marketCap":5216540423},{"date":"2023-09-22","current":16.76524,"twenty":22.132664,"median":26.581405,"eighty":47.708717,"marketCap":4980517055},{"date":"2023-09-29","current":15.842296,"twenty":22.071204,"median":26.533855,"eighty":47.733513,"marketCap":4706334221},{"date":"2023-10-06","current":15.699573,"twenty":22.00403,"median":26.476535,"eighty":47.733513,"marketCap":4663934814},{"date":"2023-10-13","current":15.985019,"twenty":21.941181,"median":26.439984,"eighty":47.733513,"marketCap":4748733628},{"date":"2023-10-20","current":15.875598,"twenty":21.917751,"median":26.407224,"eighty":47.758308,"marketCap":4716227416},{"date":"2023-10-27","current":15.74239,"twenty":21.883916,"median":26.38613,"eighty":47.822624,"marketCap":4676654636},{"date":"2023-11-03","current":20.803751,"twenty":21.866782,"median":26.2991,"eighty":47.822624,"marketCap":5386132717},{"date":"2023-11-10","current":20.863798,"twenty":21.816731,"median":26.240737,"eighty":47.822624,"marketCap":5401679151},{"date":"2023-11-17","current":22.031997,"twenty":21.780722,"median":26.064257,"eighty":47.822624,"marketCap":5704127958},{"date":"2023-11-24","current":22.359529,"twenty":21.780722,"median":25.985145,"eighty":47.822624,"marketCap":5788926689},{"date":"2023-12-01","current":22.54513,"twenty":21.780722,"median":25.946161,"eighty":47.822624,"marketCap":5836979303},{"date":"2023-12-07","current":22.927251,"twenty":21.780555,"median":25.927715,"eighty":47.837348,"marketCap":5935911156},{"date":"2023-12-14","current":23.669657,"twenty":21.780389,"median":25.885891,"eighty":47.852073,"marketCap":6128121612},{"date":"2023-12-22","current":23.838882,"twenty":21.780222,"median":25.864321,"eighty":47.866797,"marketCap":6171934290},{"date":"2023-12-29","current":24.253756,"twenty":21.780055,"median":25.813567,"eighty":47.881521,"marketCap":6279346015},{"date":"2024-01-05","current":23.964436,"twenty":21.778523,"median":25.768364,"eighty":47.901144,"marketCap":6204440470},{"date":"2024-01-12","current":24.646795,"twenty":21.778523,"median":25.744647,"eighty":47.901144,"marketCap":6381104492},{"date":"2024-01-19","current":23.314831,"twenty":21.77699,"median":25.711108,"eighty":47.920767,"marketCap":6036256320},{"date":"2024-01-23","current":23.132655,"twenty":21.77699,"median":25.699054,"eighty":47.920767,"marketCap":5989090759}],"updateTime":1746599912089}}}